Navigation Links
New Data Show Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Demonstrated Significant ADHD Symptom Reduction when Assessed Using the Oppositional Subscale of the Conners' ADHD Rating Scale
Date:10/29/2009

HONOLULU, Oct. 29 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced new study results on INTUNIV(TM) (guanfacine) Extended Release Tablets, at a major psychiatric medical meeting today. The primary objective of this study was to assess the change from baseline on the oppositional subscale of the Conners' Parent Rating Scale-Revised: Long Form (CPRS-R:L) in patients ages 6 to 12 with a primary diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) with the presence of oppositional symptoms at baseline. INTUNIV met the primary objective demonstrating significant efficacy in reducing symptoms as measured by the oppositional subscale. Some of the symptoms measured by this scale include deliberately doing things that annoy others, refusing to comply with adults' requests, and being touchy or easily annoyed by others.

According to the Centers for Disease Control and Prevention (CDC), approximately 7.8 percent of all US school-aged children have been diagnosed with ADHD at some point in their lives. ADHD is a complex neurobehavioral disorder, which includes symptoms and behaviors such as inattentiveness, running around or climbing excessively, and being excitable or impulsive, many of which can be disruptive.

"The disruptive nature of ADHD can impact social and academic settings for those patients diagnosed with the disorder," said F. Randy Sallee, MD, PhD, Professor of Psychiatry at the University of Cincinnati and Cincinnati Children's Hospital Medical Center in Cincinnati, Ohio. "This study showed that INTUNIV is an effective option for treating a
'/>"/>

SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
2. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
3. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
4. ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom(TM) QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting
5. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
6. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
7. CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
8. ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
9. New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) is as Effective as Glargine over a 24-Hour Period in Subjects with Type 2 Diabetes
10. Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
11. U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ...
(Date:1/15/2014)... Jan. 15, 2014  A novel wearable injector slightly larger than ... for patients to self-inject prescription drugs in the large doses ... blood diseases, autoimmune deficiencies, and genetic disorders.  ... $220B by 2018, according to analysts.   Many of these drugs ...
(Date:1/14/2014)... North America,s leading business partnering event ... 30 th edition of its annual conference at the ... 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... specialty chemical companies will take part in the conference, which ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... Cardinal Health today announced the launch of its new ... increase efficiencies and minimize waste in acute drainage, biopsy ... trays include the essential clinical supplies needed for each ... organizing supplies for procedures and the amount of waste ...
... Pharmaceuticals International, Inc. (NYSE: VRX ... acquired Probiotica Laboratorios Ltda., a leader in sports ... markets a full line of over-the-counter sports nutrition ... percent share of the market. Valeant will acquire ...
Cached Medicine Technology:Cardinal Health Introduces Diagnostic Procedure Trays 2Valeant Pharmaceuticals Acquires Probiotica in Brazil 2
(Date:4/24/2014)... scientist at the University of York reveals that a ... of the nervous system may also play a pivotal ... research team, led by Dr Will Brackenbury, a Medical ... York, has studied how voltage-gated sodium channels assist in ... in the membranes of excitable cells, such as neurons, ...
(Date:4/23/2014)... 24, 2014 Pregnant immigrants from Sub-Saharan Africa, ... monitoring during pregnancy, according to new research from ... in the British Journal of Obstetrics and ... eclampsia rates among immigrants and native-born women in ... Denmark, Sweden, Spain (Catalonia and Valencia) and the ...
(Date:4/23/2014)... John J. O,Shea, M.D., scientific director at the National ... has been named the 2014 recipient of the Ross ... peer-reviewed, open-access journal Molecular Medicine . The award ... York Academy of Sciences in Manhattan, followed by scientific ... is part of the National Institutes of Health. , ...
(Date:4/23/2014)... that rats exposed to high-energy particles, simulating conditions astronauts ... lapses in attention and slower reaction times, even when ... , The cognitive impairments which affected a large ... appear to be linked to protein changes in the ... hold true in humans, suggest it may be possible ...
(Date:4/23/2014)... A novel compound that targets an important brain ... cocaine addiction behaviors, including relapse behavior, a University at ... strong evidence that this may be a novel lead ... medications exist., The UB research was published as an ... , In the study, the compound, RO5263397, severely blunted ...
Breaking Medicine News(10 mins):Health News:Breast cancer replicates brain development process 2Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3Health News:Novel compound halts cocaine addiction and relapse behaviors 2
... the age of forty with breast cancer who are given ... chemotherapy, may not be benefiting from these drugs. This is ... hormones such as estrogen, according to research published in the ... a young age is very worrying in terms of survival," ...
... Benefit, MARYSVILLE, Calif., Oct. 10 Yuba County ... filing of a,formal grievance over the county,s refusal to ... year. Because of the county,s unwillingness to abide ... elderly or have disabilities must play,a waiting game with ...
... Pa., Oct. 10 The following is,being issued by the Pennsylvania Breast Cancer Coalition:, WHAT: ... of the Pennsylvania Breast ... two-day event, held every October, is the premiere breast ... thousand attendees participate ...
... key protein that controls how stem cells choose to ... smooth muscle cells that support blood vessels, according to ... National Academy of Sciences (PNAS). The results not ... in the human fetus, but also suggest new ways ...
... (pronounced,zy-ince), one of the fastest growing brands in the ... has received access,to up to $12 million in a ... intends to use a significant portion of the,investment to ... Xenergy is a combination of Zen and Energy and ...
... say , WEDNESDAY, Oct. 10 (HealthDay News) -- Adult stem ... stem cells in an undifferentiated state, U.S. researchers report. , ... change into any kind of cell is regulated differently in ... also challenges findings from more than 50 studies that concluded ...
Cached Medicine News:Health News:Cancer conflict with chemotherapy treatment 2Health News:Caregivers Demand County Honor Their Contract 2Health News:PA Breast Cancer Coalition Announces Special Press Availability for PA Breast Cancer Coalition Annual Conference 2Health News:Study reveals how stem cells decide to become either skeletal or smooth muscle 2Health News:Study reveals how stem cells decide to become either skeletal or smooth muscle 3Health News:Study reveals how stem cells decide to become either skeletal or smooth muscle 4Health News:Study reveals how stem cells decide to become either skeletal or smooth muscle 5Health News:XYIENCE(R) Announces $12 Million Funding and Signing of Long Term UFC(R) Sponsorship 2Health News:Study Probes Difference Between Embryonic, Adult Stem Cells 2
... Single Use linear stapler with ... Auto Suture™ PREMIUM POLY CS™-57 disposable ... creation of a temporary opening, such ... cesarean section, or when transecting muscle ...
... Use reloadable linear stapler ... (DST™) titanium staples., ... Reloadable staplers has application ... and thoracic surgical procedures ...
... reloadable linear stapler for resection, transection and ... Suture™ MULTIFIRE GIA™ 60 and 80 single ... and 80 single use loading units and ... single use surgical stapler with MULTIFIRE SGIA™ ...
... With Titanium Staples for use with PI™ ... ,The PI™ disposable stapler is designed ... of normal, healthy internal tissues. The instrument ... staggered row, when using the 30 VASCULAR ...
Medicine Products: